Cargando…

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting

BACKGROUND: Patients with hepatitis C virus (HCV) genotype 3 infection remain a difficult-to-cure population. This study evaluated the efficacy and safety of sofosbuvir-based regimen in genotype 3 patients in a real-world setting. METHODS: HCV genotype 3a-infected adults with compensated liver disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Qunying, Fan, Xiude, Wang, Xiaoyun, Wang, Ye, Deng, Huan, Zhang, Xiaoge, Zhang, Kun, Li, Na, Liu, Zhengwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547524/
https://www.ncbi.nlm.nih.gov/pubmed/31159813
http://dx.doi.org/10.1186/s12985-019-1184-y
_version_ 1783423696940040192
author Han, Qunying
Fan, Xiude
Wang, Xiaoyun
Wang, Ye
Deng, Huan
Zhang, Xiaoge
Zhang, Kun
Li, Na
Liu, Zhengwen
author_facet Han, Qunying
Fan, Xiude
Wang, Xiaoyun
Wang, Ye
Deng, Huan
Zhang, Xiaoge
Zhang, Kun
Li, Na
Liu, Zhengwen
author_sort Han, Qunying
collection PubMed
description BACKGROUND: Patients with hepatitis C virus (HCV) genotype 3 infection remain a difficult-to-cure population. This study evaluated the efficacy and safety of sofosbuvir-based regimen in genotype 3 patients in a real-world setting. METHODS: HCV genotype 3a-infected adults with compensated liver disease were treated with sofosbuvir (SOF)/velpatasvir (VEL) or SOF/daclatasvir (DCV) with or without ribavirin (RBV) for 12 or 24 weeks, respectively. Efficacy was measured by sustained virologic response at post-treatment week 12 (SVR12). Adverse events were evaluated throughout the treatment and follow-up course. RESULTS: A total of 41 genotype 3a-infected patients were included. Of them, 10 patients (24%) had cirrhosis, 3 (7%) had renal impairment, and 2 (5%) failed previous treatment. Nine patients (22%) were treated with SOF/VEL and 32 (78%) with SOF/DCV with or without RBV. SVR 12 was achieved in 100% (9/9) of patients treated with SOF/VEL for 12 weeks and in 97% (31/32) of those treated with SOF/DCV for 12 or 24 weeks. RBV addition and extension of treatment duration did not improve the SVR of SOF/DCV (RR: 1.04; P = 0.99 and RR: 1.09; P = 0.375, respectively). Ten patients with cirrhosis, 1 on hemodialysis and 2 with treatment-experience achieved SVR12. One treatment-naïve non-cirrhotic patient on hemodialysis treated with SOF/DCV for 24 weeks relapsed at week 8 post-treatment. No serious adverse events and relevant laboratory abnormalities were observed. CONCLUSION: SOF/VEL and SOF/DCV are highly efficacious and well tolerated in genotype 3a-infected patients with or without cirrhosis. RBV coadministration and extension of SOF/DCV treatment appear to add no improvement for efficacy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-019-1184-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6547524
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65475242019-06-06 High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting Han, Qunying Fan, Xiude Wang, Xiaoyun Wang, Ye Deng, Huan Zhang, Xiaoge Zhang, Kun Li, Na Liu, Zhengwen Virol J Research BACKGROUND: Patients with hepatitis C virus (HCV) genotype 3 infection remain a difficult-to-cure population. This study evaluated the efficacy and safety of sofosbuvir-based regimen in genotype 3 patients in a real-world setting. METHODS: HCV genotype 3a-infected adults with compensated liver disease were treated with sofosbuvir (SOF)/velpatasvir (VEL) or SOF/daclatasvir (DCV) with or without ribavirin (RBV) for 12 or 24 weeks, respectively. Efficacy was measured by sustained virologic response at post-treatment week 12 (SVR12). Adverse events were evaluated throughout the treatment and follow-up course. RESULTS: A total of 41 genotype 3a-infected patients were included. Of them, 10 patients (24%) had cirrhosis, 3 (7%) had renal impairment, and 2 (5%) failed previous treatment. Nine patients (22%) were treated with SOF/VEL and 32 (78%) with SOF/DCV with or without RBV. SVR 12 was achieved in 100% (9/9) of patients treated with SOF/VEL for 12 weeks and in 97% (31/32) of those treated with SOF/DCV for 12 or 24 weeks. RBV addition and extension of treatment duration did not improve the SVR of SOF/DCV (RR: 1.04; P = 0.99 and RR: 1.09; P = 0.375, respectively). Ten patients with cirrhosis, 1 on hemodialysis and 2 with treatment-experience achieved SVR12. One treatment-naïve non-cirrhotic patient on hemodialysis treated with SOF/DCV for 24 weeks relapsed at week 8 post-treatment. No serious adverse events and relevant laboratory abnormalities were observed. CONCLUSION: SOF/VEL and SOF/DCV are highly efficacious and well tolerated in genotype 3a-infected patients with or without cirrhosis. RBV coadministration and extension of SOF/DCV treatment appear to add no improvement for efficacy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-019-1184-y) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-03 /pmc/articles/PMC6547524/ /pubmed/31159813 http://dx.doi.org/10.1186/s12985-019-1184-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Han, Qunying
Fan, Xiude
Wang, Xiaoyun
Wang, Ye
Deng, Huan
Zhang, Xiaoge
Zhang, Kun
Li, Na
Liu, Zhengwen
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
title High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
title_full High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
title_fullStr High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
title_full_unstemmed High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
title_short High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
title_sort high sustained virologic response rates of sofosbuvir-based regimens in chinese patients with hcv genotype 3a infection in a real-world setting
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547524/
https://www.ncbi.nlm.nih.gov/pubmed/31159813
http://dx.doi.org/10.1186/s12985-019-1184-y
work_keys_str_mv AT hanqunying highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting
AT fanxiude highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting
AT wangxiaoyun highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting
AT wangye highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting
AT denghuan highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting
AT zhangxiaoge highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting
AT zhangkun highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting
AT lina highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting
AT liuzhengwen highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting